For primary breast cancer, the determination of uPA and PAI-1 antigen levels in tumour tissue extracts has already entered clinical practice for risk stratification and individual therapy decisions in patients with lymph node-negative disease[16, 38]. This evidence concerns the gene SERPINE1 and breast carcinoma.